Cancer is one of the leading causes of morbidity and mortality around the world. Despite some success, traditional anticancer drugs developed to reduce tumor growth face important limitations primarily due to undesirable bone marrow and cardiovascular toxicity. Many drugs fail in clinical development after showing promise in preclinical trials, suggesting that the available in vitro and animal models are poor predictors of drug efficacy and toxicity in humans. Thus, novel models that more accurately mimic the biology of human organs are necessary for high-throughput drug screening. Three-dimensional (3D) microphysiological systems can utilize induced pluripotent stem cell technology, tissue engineering, and microfabrication techniques to develop tissue models of human tumors, cardiac muscle, and bone marrow on the order of 1 mm3 in size. A functional network of human capillaries and microvessels to overcome diffusion limitations in nutrient delivery and waste removal can also nourish the 3D microphysiological tissues. Importantly, the 3D microphysiological tissues are grown on optically clear platforms that offer non-invasive and non-destructive image acquisition with subcellular resolution in real time. Such systems offer a new paradigm for high-throughput drug screening and will significantly improve the efficiency of identifying new drugs for cancer treatment that minimize cardiac and bone marrow toxicity.
MarshJC. The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: A review. Cancer Res1976; 36: 1853–82.
2.
DempkeWVon PoblozkiAGrotheyASchmollHJ. Human hematopoietic growth factors: Old lessons and new perspectives. Anticancer Res2000; 20: 5155–64.
3.
TestaNGHendryJHMolineuxG. Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res1985; 5: 101–10.
4.
AlbiniAPennesiGDonatelliFCammarotaRDe FloraSNoonanDM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst2010; 102: 14–25.
Todaro MC, Oreto L, Qamar R, Paterick TE, Carerj S, Khandheria BK. Cardioncology: State of the heart. Int J Cardiol 2013;168:680–7.
7.
GriffithLGSwartzMA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol2006; 7: 211–24.
8.
LoATMoriHMottJBissellMJ. Constructing three-dimensional models to study mammary gland branching morphogenesis and functional differentiation. J Mammary Gland Biol Neoplasia2012; 17: 103–10.
9.
RoskelleyCDDesprezPYBissellMJ. Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Natl Acad Sci USA1994; 91: 12378–82.
10.
SchyschkaLSanchezJJWangZBurkhardtBMuller-VieiraUZeilingerKBachmannANadalinSDammGNusslerAK. Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity. Arch Toxicol2013; 87: 1581–93.
11.
DalenHBurkiHJ. Some observations on the three-dimensional growth of L5178Y cell colonies in soft agar culture. Exp Cell Res1971; 65: 433–8.
12.
Feder-MengusCGhoshSReschnerAMartinISpagnoliGC. New dimensions in tumor immunology: What does 3D culture reveal?Trends Mol Med2008; 14: 333–40.
13.
WangFWeaverVMPetersenOWLarabellCADedharSBriandPLupuRBissellMJ. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: A different perspective in epithelial biology. Proc Natl Acad Sci USA1998; 95: 14821–6.
14.
ValcarcelMArtetaBJaureguibeitiaALopategiAMartinezIMendozaLMuruzabalFJSaladoCVidal-VanaclochaF. Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: Implications on hepatic micrometastasis. J Transl Med2008; 6: 57–57.
YamazakiDKurisuSTakenawaT. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. Oncogene2009; 28: 1570–83.
17.
BeningoKADemboMWangYL. Responses of fibroblasts to anchorage of dorsal extracellular matrix receptors. Proc Natl Acad Sci USA2004; 101: 18024–9.
18.
HorningJLSahooSKVijayaraghavaluSDimitrijevicSVasirJKJainTKPandaAKLabhasetwarV. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm2008; 5: 849–62.
19.
DoublierSBelisarioDCPolimeniMAnnaratoneLRigantiCAlliaEGhigoDBosiaASapinoA. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: A potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer2012; 12: 4–4.
20.
ChitcholtanKAsselinEParentSSykesPHEvansJJ. Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. Exp Cell Res2013; 319: 75–87.
21.
HowesALChiangGGLangESHoCBPowisGVuoriKAbrahamRT. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther2007; 6: 2505–14.
22.
WeigeltBLoATParkCCGrayJWBissellMJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat2010; 122: 35–43.
23.
AssadianSEl-AssaadWWangXQGannonPOBarresVLatourMMes-MassonAMSaadFSadoYDostieJTeodoroJG. p53 inhibits angiogenesis by inducing the production of Arresten. Cancer Res2012; 72: 1270–9.
24.
Millerot-SerrurotEGuilbertMFourreNWitkowskiWSaidGVan GulickLTerrynCZahmJMGarnotelRJeannessonP. 3D collagen type I matrix inhibits the antimigratory effect of doxorubicin. Cancer Cell Int2010; 10: 26–26.
25.
CarmelietPJainRK. Angiogenesis in cancer and other diseases. Nature2000; 407: 249–57.
26.
HelmlingerGYuanFDellianMJainRK. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med1997; 3: 177–82.
27.
MuschlerGFNakamotoCGriffithLG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am2004; 86-A: 1541–58.
28.
ZhangJFriedmanMH. Adaptive response of vascular endothelial cells to an acute increase in shear stress magnitude. Am J Physiol Heart Circ Physiol2012; 302: H983–91.
29.
CinesDBPollakESBuckCALoscalzoJZimmermanGAMcEverRPPoberJSWickTMKonkleBASchwartzBSBarnathanESMcCraeKRHugBASchmidtAMSternDM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood1998; 91: 3527–61.
30.
JohnsonJIDeckerSZaharevitzDRubinsteinLVVendittiJMSchepartzSKalyandrugSChristianMArbuckSHollingsheadMSausvilleEA. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer2001; 84: 1424–31.
31.
CheZMJungTHChoiJHYoonDJJeongHJLeeEJKimJ. Collagen-based co-culture for invasive study on cancer cells-fibroblasts interaction. Biochem Biophys Res Commun2006; 346: 268–75.
32.
SutherlandRMMccredieJAInchWR. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst1971; 46: 113–20.
33.
TanakaRSaitoTAshiharaKNishimuraMMizumotoHKudoR. Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells. Gynecol Oncol2003; 90: 297–304.
34.
JainRK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science2005; 307: 58–62.
35.
JainRK. Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology (Williston Park)2005; 19: 7–16.
36.
LeuAJBerkDALymboussakiAAlitaloKJainRK. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res2000; 60: 4324–7.
37.
PaderaTPKadambiAdi TomasoECarreiraCMBrownEBBoucherYChoiNCMathisenDWainJMarkEJMunnLLJainRK. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science2002; 296: 1883–6.
38.
JainRK. Barriers to drug-delivery in solid tumors. Sci Am1994; 271: 58–65.
39.
RutkowskiJMSwartzMA. A driving force for change: Interstitial flow as a morphoregulator. Trends Cell Biol2007; 17: 44–50.
40.
JainRK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng1999; 1: 241–63.
41.
HockelMVaupelP. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst2001; 93: 266–76.
42.
MinchintonAITannockIF. Drug penetration in solid tumours. Nat Rev Cancer2006; 6: 583–92.
43.
Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P, Buchler MW, Herr I. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One 2012;7.
44.
ComerfordKMWallaceTJKarhausenJLouisNAMontaltoMCColganSP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res2002; 62: 3387–94.
45.
HsuYHMoyaMLAbiriPHughesCCGeorgeSCLeeAP. Full range physiological mass transport control in 3D tissue cultures. Lab Chip2013; 13: 81–9.
46.
KimSLeeHChungMJeonNL. Engineering of functional, perfusable 3D microvascular networks on a chip. Lab Chip2013; 13: 1489–500.
47.
MoyaMLHsuYHLeeAPHughesCCWGeorgeSC. In vitro perfused human capillary networks. Tissue Eng Part C Methods2013; 19: 730–7.
48.
WiigHSwartzMA. Interstitial fluid and lymph formation and transport: Physiological regulation and roles in inflammation and cancer. Physiol Rev2012; 92: 1005–60.
EgebladMNakasoneESWerbZ. Tumors as organs: Complex tissues that interface with the entire organism. Dev Cell2010; 18: 884–901.
51.
SchedinPMitrengaTMcDanielSKaeckM. Mammary ECM composition and function are altered by reproductive state. Mol Carcinog2004; 41: 207–20.
52.
Fleming JM, Miller TC, Quinones M, Xiao Z, Xu X, Meyer MJ, Ginsburg E, Veenstra TD, Vonderhaar BK. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med 2010;8.
53.
LinEYLiJFGnatovskiyLDengYZhuLGrzesikDAQianHXueXNPollardJW. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res2006; 66: 11238–46.
54.
KalluriRZeisbergM. Fibroblasts in cancer. Nat Rev Cancer2006; 6: 392–401.
55.
ChenXFAlediaASPopsonSAHimLHughesCCWGeorgeSC. Rapid anastomosis of endothelial progenitor cell-derived vessels with host vasculature is promoted by a high density of cotransplanted fibroblasts. Tissue Eng Part A2010; 16: 585–94.
56.
De PalmaMLewisCE. Cancer macrophages limit chemotherapy. Nature2011; 472: 303–4.
EwerMSEwerSM. Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cardiol2010; 7: 564–75.
59.
RaschiEVasinaVUrsinoMGBorianiGMartoniADe PontiF. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol Ther2010; 125: 196–218.
60.
YehETBickfordCL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol2009; 53: 2231–47.
61.
MonsuezJJCharniotJCVignatNArtigouJY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol2010; 144: 3–15.
62.
BonitaRPradhanR. Cardiovascular toxicities of cancer chemotherapy. Semin Oncol2013; 40: 156–67.
63.
FrenchKMBoopathyAVDeQuachJAChingozhaLLuHChristmanKLDavisME. A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro. Acta Biomater2012; 8: 4357–64.
64.
DasBAntoonRTsuchidaRLotfiSMorozovaOFarhatWMalkinDKorenGYegerHBaruchelS. Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth. Neoplasia2008; 10: 1105–19.
65.
SaloustrosETryfonidisKGeorgouliasV. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opin Pharmacother2011; 12: 851–63.
66.
RandallTDWeissmanIL. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood1997; 89: 3596–606.
67.
HsuYHMoyaMLAbiriPHughesCCGeorgeSCLeeAP. Full range physiological mass transport control in 3D tissue cultures. Lab Chip2013; 13: 81–9.
68.
Moya ML, Hsu YH, Lee AP, Hughes CC, George SC. In vitro perfused human capillary networks. Tissue Eng Part C Methods 2013;19:730–7.
69.
Hsu YH, Moya ML, Hughes CC, George SC, Lee AP. A microfluidic platform for generating large-scale nearly identical human microphysiological vascularized tissue arrays. Lab Chip 2013;13:2990–8.
GriffithCKMillerCSainsonRCCalvertJWJeonNLHughesCCGeorgeSC. Diffusion limits of an in vitro thick prevascularized tissue. Tissue Eng2005; 11: 257–66.
72.
ThompsonHGMihJDKrasievaTBTrombergBJGeorgeSC. Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis. Am J Physiol Lung Cell Mol Physiol2006; 291: L1277–85.
73.
WikswoJPBlockFE3rdCliffelDEGoodwinCRMarascoCCMarkovDAMcLeanDLMcLeanJAMcKenzieJRReisererRSSamsonPCSchafferDKSealeKTSherrodSD. Engineering challenges for instrumenting and controlling integrated organ-on-chip systems. IEEE Trans Biomed Eng2013; 60: 682–90.
74.
WikswoJPCurtisELEagletonZEEvansBCKoleAHofmeisterLHMatloffWJ. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip2013; 13: 3496–511.
75.
WilliamsLRLeggettRW. Reference values for resting blood flow to organs of man. Clin Phys Physiol Meas1989; 10: 187–217.
76.
StringariCCinquinACinquinODigmanMADonovanPJGrattonE. Phasor approach to fluorescence lifetime microscopy distinguishes different metabolic states of germ cells in a live tissue. Proc Natl Acad Sci USA2011; 108: 13582–7.
XiJKhalilMShishechianNHannesTPfannkucheKLiangHFatimaAHausteinMSuhrFBlochWReppelMSaricTWernigMJanischRBrockmeierKHeschelerJPillekampF. Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J2010; 24: 2739–51.
81.
GibsonRJBowenJM. Biomarkers of regimen-related mucosal injury. Cancer Treat Rev2011; 37: 487–93.
82.
XueHSawyerMBWischmeyerPEBaracosVE. Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: From preclinical findings to clinical strategy. JPEN J Parenter Enteral Nutr2011; 35: 74–90.
83.
MaorYMalnickS. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol2013; 2013: 815105–815105.
84.
PablaNDongZ. Curtailing side effects in chemotherapy: A tale of PKCdelta in cisplatin treatment. Oncotarget2012; 3: 107–11.
GilliamLASt ClairDK. Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress. Antioxid Redox Signal2011; 15: 2543–63.
88.
van NorrenKvan HelvoortAArgilesJMvan TuijlSArtsKGorselinkMLavianoAKeglerDHaagsmanHPvan der BeekEM. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer2009; 100: 311–4.
89.
BlumenfeldZ. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol2012; 26: 379–90.
90.
RaghebAMSabaneghESJr. Male fertility-implications of anticancer treatment and strategies to mitigate gonadotoxicity. Anticancer Agents Med Chem2010; 10: 92–102.
91.
HoekstraRNibourgGAvan der HoevenTVPlomerGSeppenJAckermansMTCamusSKulikWvan GulikTMElferinkRPChamuleauRA. Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide. Drug Metab Dispos2013; 41: 562–7.
92.
HilmerSNShenfieldGMLe CouteurDG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag2005; 1: 151–6.
93.
JangKJMehrAPHamiltonGAMcPartlinLAChungSSuhKYIngberDE. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol (Camb)2013; 5: 1119–29.
94.
Ould-DrisAPaullierPGriscomLLegallaisCLeclercE. Analysis of the mass transfers in an artificial kidney microchip. J Membr Sci2010; 352: 116–125.
95.
NaikPCuculloL. In vitro blood-brain barrier models: Current and perspective technologies. J Pharm Sci2012; 101: 1337–54.
96.
PedersenBK. Muscles and their myokines. J Exp Biol2011; 214: 337–46.
97.
Al MoundhriMSAl-SalamSAl MahrouqeeABeegamSAliBH. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: Some behavioral, biochemical, and histopathological studies. J Med Toxicol2013; 9: 25–33.
98.
LiCLTianTNanKJZhaoNGuoYHCuiJWangJZhangWG. Survival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro. Oncol Rep2008; 20: 1465–71.
99.
DavidLDulongVLe CerfDCazinLLamaczMVannierJP. Hyaluronan hydrogel: An appropriate three-dimensional model for evaluation of anticancer drug sensitivity. Acta Biomater2008; 4: 256–63.
100.
FujiwaraDKatoKNoharaSIwanumaYKajiyamaY. The usefulness of three-dimensional cell culture in induction of cancer stem cells from esophageal squamous cell carcinoma cell lines. Biochem Biophys Res Commun2013; 434: 773–8.
101.
GurskiLAJhaAKZhangCJiaXFarach-CarsonMC. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials2009; 30: 6076–85.
102.
PadronJMvan der WiltCLSmidKSmitskamp-WilmsEBackusHHPizaoPEGiacconeGPetersGJ. The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol2000; 36: 141–57.
103.
NirmalanandhanVSDurenAHendricksPVielhauerGSittampalamGS. Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev Technol2010; 8: 581–90.
104.
MiyamotoHMurakamiTTsuchidaKSuginoHMiyakeHTashiroS. Tumor-stroma interaction of human pancreatic cancer: Acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas2004; 28: 38–44.
105.
MuerkosterSWegehenkelKArltAWittMSiposBKruseMLSebensTKloppelGKalthoffHFolschURSchaferH. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res2004; 64: 1331–7.
106.
SerebriiskiiICastello-CrosRLambAGolemisEACukiermanE. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol2008; 27: 573–85.
107.
GoelSDudaDGXuLMunnLLBoucherYFukumuraDJainRK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev2011; 91: 1071–121.
108.
ThorpePE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res2004; 10: 415–27.
109.
PetersGJSmitskamp-WilmsESmidKPinedoHMJansenG. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res1999; 59: 5529–35.
110.
HicksKOPruijnFBSecombTWHayMPHsuRBrownJMDennyWADewhirstMWWilsonWR. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst2006; 98: 1118–28.
111.
AgastinSGiangUBGengYDelouiseLAKingMR. Continuously perfused microbubble array for 3D tumor spheroid model. Biomicrofluidics2011; 5: 24110–24110.
112.
ChenSYHungPJLeePJ. Microfluidic array for three-dimensional perfusion culture of human mammary epithelial cells. Biomed Microdevices2011; 13: 753–8.
113.
MasurKNiggemannBZankerKSEntschladenF. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res2001; 61: 2866–9.
114.
PasquierECiccoliniJCarreMGiacomettiSFanciullinoRPouchyCMonteroMPSerdjebiCKavallarisMAndreN. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: Implication in breast cancer treatment. Oncotarget2011; 2: 797–809.
115.
Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 2013;272:245–55.
116.
DoldererJHSchuldesHBockhornHAltmannsbergerMLambersCvon ZabernDJonasDSchweglerHLinkeRSchroderUH. HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol2010; 36: 72–7.
117.
GlassmeierGHempelKWulfsenIBauerCKSchumacherUSchwarzJR. Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells. Pflugers Arch2012; 463: 365–76.
RuoslahtiE. Specialization of tumour vasculature. Nat Rev Cancer2002; 2: 83–90.
120.
LevesqueJPWinklerIG. It takes nerves to recover from chemotherapy. Nat Med2013; 19: 669–71.
121.
SchimmelKJRichelDJvan den BrinkRBGuchelaarHJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev2004; 30: 181–91.
122.
WangYProbinVZhouD. Cancer therapy-induced residual bone marrow injury – Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev2006; 2: 271–9.
ForceTKrauseDSVan EttenRA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer2007; 7: 332–44.
125.
RaschiEDe PontiF. Cardiovascular toxicity of anticancer-targeted therapy: Emerging issues in the era of cardio-oncology. Intern Emerg Med2012; 7: 113–31.
126.
EwerMSLippmanSM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol2005; 23: 2900–2.
127.
TelliMLHuntSACarlsonRWGuardinoAE. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol2007; 25: 3525–33.
128.
WoutersBGKoritzinskyM. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer2008; 8: 851–64.
129.
ShinDHChunYSLeeDSHuangLEParkJW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood2008; 111: 3131–6.
130.
EllisLHammersHPiliR. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett2009; 280: 145–53.
131.
GarberK. Angiogenesis inhibitors suffer new setback. Nat Biotechnol2002; 20: 1067–8.
132.
KruzliakPKovacovaGPechanovaO. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis2013; 16: 289–95.
